secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2024-07-24T23:59:59+00:00
Accession:  0001628280-24-032815
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo Phase 3 hemophilia A gene therapy meets primary endpoint with superiority over prophylaxis
--------------------------------------------------------------------------------

- AFFINE trial achieved superiority on total ABR (1.24 vs 4.73, p=0.0040) compared to FVIII prophylaxis.
- 84% of participants maintained FVIII activity >5% at 15 months; mean treated ABR reduced 98.3% (0.07 vs 4.08, p<0.0001).
- Sangamo eligible for up to $220M in regulatory/commercial milestones plus 14%-20% royalties on sales.
- One participant (1.3%) returned to prophylaxis; treatment generally well tolerated with transient elevated FVIII in 49.3%.
- Pfizer to discuss data with regulatory authorities; Sangamo's first potential commercial medicine.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000162828024032815/0001628280-24-032815-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000162828024032815/sgmo-20240724.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-032815

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer